Canada recommends Johnson & Johnson vaccine for all Canadians over 30

Canada recommends Johnson & Johnson vaccine for all Canadians over 30


The Johnson & Johnson vaccine is now recommended for all Canadians over 30, but officials say to weigh the risk of rare but potentially serious blood clots that can occur from the vaccine with the COVID-19 levels in their community — or hold out for another shot altogether.

The National Advisory Committee on Immunization (NACI) said Monday that while the Johnson & Johnson vaccine will soon be distributed across Canada, it’s up to Canadians over 30 to decide whether they should take it or wait for an mRNA vaccine such as Pfizer-BioNTech or Moderna.

Health Canada approved the Johnson & Johnson vaccine in March and updated its labelling last week to acknowledge the risk of a rare but serious blood-clotting condition connected to the shot known as vaccine-induced immune thrombotic thrombocytopenia (VITT).

The move followed a brief pause of the Johnson & Johnson vaccine in the U.S. to investigate reports of clots, which NACI officials said Monday have occurred in 17 of the roughly eight million Americans who have received the shot.

VITT has also been reported with the AstraZeneca-Oxford COVID-19 vaccine in Canada, and like the J&J vaccine, it uses a similar adenovirus vector technology, which has led to unproven speculation that the rare condition could be connected to the vaccine platform.

NACI says VITT occurs at a rate of about one in 100,000 people vaccinated with the AstraZeneca vaccine, with a mortality rate of about 40 per cent, although more research is needed — and that number is subject to change.

Though extremely rare, VITT is much more severe than a typical blood clot because it can cause cerebral venous sinus thrombosis (CVST), where veins that drain blood from the brain are obstructed and can potentially cause fatal bleeding.

Also Read:  Mother of child killed in fire west of Edmonton thanks community for support - Edmonton

Canada has reported seven confirmed cases of VITT following the AstraZeneca vaccine out of more than 1.1 million doses administered. One death was reported in Quebec on Saturday, when a 54-year-old woman died of CVST in a Montreal hospital after receiving the AstraZeneca shot on April 9.

NACI also announced Monday that mRNA vaccines, such as Pfizer-BioNTech and Moderna, are preferred in pregnant women and that Canadians who have previously been infected with COVID-19 should still receive two doses of a vaccine rather than one, which was previously recommended. 

More to come


News Source

Leave a reply

Please enter your comment!
Please enter your name here